1t(?)-(2-methyl-[1,3]dioxolan-2-yl)-oct-1-ene | 4420-47-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1t(?)-(2-methyl-[1,3]dioxolan-2-yl)-oct-1-ene
• 英文别名: 1t-(2-methyl-[1,3]dioxolan-2-yl)-oct-1-ene；1t-(2-Methyl-[1,3]dioxolan-2-yl)-oct-1-en
• CAS: 4420-47-7
• 化学式: C₁₂H₂₂O₂
• 分子量: 198.305
• InChiKey: OKSMPANVTGTGGI-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.28
• 重原子数：
  14.0
• 可旋转键数：
  6.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  18.46
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为产物：
  描述：

  2-(溴甲基)-2-甲基-1,3-二氧戊环 、 乙基溴化镁 在 乙醚 、 苯 作用下， 生成 2,2'-亚乙基双(2-甲基-1,3-二氧戊环) 、 1t(?)-(2-methyl-[1,3]dioxolan-2-yl)-oct-1-ene
  参考文献：
  名称：

  Nutrient Support in Hematopoietic Cell Transplantation

  摘要：

  High‐dose cytoreduction and hematopoietic stem cell infusion form the basis for treatment of hematologic cancers, defects or failure of hematopoiesis, and some solid tumors. As an antitumor therapy, allogeneic hematopoietic cell transplantation (HCT) is superior to autologous HCT by induction of a graft‐us‐tumor effect. However, recipients of allografts suffer higher transplant‐related mortality owing to graft‐us‐host disease (GVHD). Nutrition support research must recognize that HCT is a heterogeneous modality whose short and long‐term outcomes are affected by transplant type, preparative regimens, diagnosis, disease stage, age, and nutritional status. The field of HCT will diversify further as lower dose cytoreduction and mixed chimerism grafts allow expansion of the technique to older patients and to other diseases. (journal of Parenteral and Enteral Nutrition 25:219–228, 2001)

  DOI：

  10.1177/0148607101025004219